Amgen (AMGN) has been making waves in the market, with various important events and trends contributing to its current status. Performing well despite market dips, AMGN has demonstrated value for long-term investments as it exceeded market returns. There's been a significant change in the holdings of AMGN, with multiple firms such as DCF Advisers LLC, Xponance Inc., and Boston Partners trimming their stocks. Conversely, TD Private Client Wealth LLC and Royal London Asset Management Ltd considerably increased their positions in AMGN. Thanks to a steady rise of ~22% YTD, AMGN’s stock sees a consistent buy-hold-sell fluctuation among investors. Positive stock performance makes Amgen a popular choice among billionaires and hedge funds. Its stock is trending due to robust financial performances in Q4 2024. The upbeat data from Uplizna's Myasthenia Gravis Study and positive outcomes from the ROACTINLIMAB Phase 3 IGNITE study show promising results. Also, AMGN has shown interesting investment strategies by investing $200M in an AI-focused Tech Center in India. Despite a few setbacks, AMGN continues to be seen as a potential best-performing Dow stock.
Amgen AMGN News Analytics from Tue, 17 Sep 2024 07:00:00 GMT to Sat, 22 Mar 2025 11:12:13 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 2
